Incyte’s Dual Strategy to Navigate Patent Cliff

As the patent protection for its blockbuster drug Jakafi approaches expiration, biopharmaceutical firm Incyte is implementing a two-pronged strategy to secure its long-term future. The company is bolstering its product pipeline through a significant regulatory approval and a key executive appointment.

This week, Incyte announced that Dave Gardner has joined the company as Executive Vice President and Chief Strategy Officer. Mr. Gardner brings more than two decades of experience in pharmaceutical investments to the role, where he will be responsible for optimizing Incyte’s development pipeline and identifying new growth opportunities. His compensation package is heavily tied to the company’s long-term performance, highlighting the importance of his strategic position. This appointment follows the departure of former CFO Christiana Stamoulis in mid-September.

Simultaneously,... Read more...